These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 36082812)

  • 1. Retrospective analysis of independent predictors of progression-free survival in patients with EGFR mutation-positive advanced non-small cell lung cancer receiving first-line osimertinib.
    Teranishi S; Sugimoto C; Nagaoka S; Nagayama H; Segawa W; Miyasaka A; Hiro S; Kajita Y; Maeda C; Kobayashi N; Yamamoto M; Kudo M; Kaneko T
    Thorac Cancer; 2022 Oct; 13(19):2741-2750. PubMed ID: 36082812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial.
    Nakashima K; Ozawa Y; Daga H; Imai H; Tamiya M; Tokito T; Kawamura T; Akamatsu H; Tsuboguchi Y; Takahashi T; Yamamoto N; Mori K; Murakami H
    Invest New Drugs; 2020 Dec; 38(6):1854-1861. PubMed ID: 32424780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status.
    Nakashima K; Kimura M; Akamatsu H; Daga H; Imai H; Taira T; Ko R; Hisamatsu Y; Nishino K; Sugimoto T; Miyashita Y; Takahashi T;
    Jpn J Clin Oncol; 2019 Jul; 49(7):671-675. PubMed ID: 30920616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis.
    Gen S; Tanaka I; Morise M; Koyama J; Kodama Y; Matsui A; Miyazawa A; Hase T; Hibino Y; Yokoyama T; Kimura T; Yoshida N; Sato M; Hashimoto N
    BMC Cancer; 2022 Jun; 22(1):654. PubMed ID: 35698083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status.
    Takamizawa S; Okuma Y; Kato Y; Hakozaki T; Kitagawa S; Zenke Y
    Future Oncol; 2022 Jan; 18(3):291-300. PubMed ID: 34758637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients.
    Hsu KH; Tseng JS; Yang TY; Chen KC; Su KY; Yu SL; Chen JJW; Huang YH; Chang GC
    Sci Rep; 2022 Jun; 12(1):9753. PubMed ID: 35697720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer.
    Hori T; Yamamoto K; Ito T; Ikushima S; Omura T; Yano I
    Invest New Drugs; 2024 Jun; 42(3):281-288. PubMed ID: 38536543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of PD-L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR-mutated NSCLC.
    Hamakawa Y; Agemi Y; Shiba A; Ikeda T; Higashi Y; Aga M; Miyazaki K; Taniguchi Y; Misumi Y; Nakamura Y; Shimokawa T; Saigusa Y; Kobayashi N; Okamoto H; Kaneko T
    Cancer Med; 2023 Sep; 12(17):17788-17797. PubMed ID: 37548381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of PD-L1 Expression on the Overall Survival of Caucasian Patients with Advanced EGFR-Mutant NSCLC Treated with Frontline Osimertinib.
    Papazyan T; Denis MG; Sagan C; Raimbourg J; Herbreteau G; Pons-Tostivint E
    Target Oncol; 2024 Jul; 19(4):611-621. PubMed ID: 38825654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP).
    Cardona AF; Ruiz-Patiño A; Recondo G; Martín C; Raez L; Samtani S; Minata JN; Blaquier JB; Enrico D; Burotto M; Ordóñez-Reyes C; Chamorro DF; Garcia-Robledo JE; Corrales L; Zatarain-Barrón ZL; Más L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Mejía S; Jaller E; Vargas C; Carranza H; Otero J; Rodríguez J; Archila P; Bermudez M; Gamez T; Cordeiro de Lima V; Freitas H; Russo A; Polo C; Malapelle U; Perez DM; Rolfo C; Viola L; Rosell R; Arrieta O
    Clin Lung Cancer; 2022 Sep; 23(6):522-531. PubMed ID: 35798634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
    Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
    Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT).
    Sakata Y; Sakata S; Oya Y; Tamiya M; Suzuki H; Shibaki R; Okada A; Kobe H; Matsumoto H; Yokoi T; Sato Y; Uenami T; Saito G; Tsukita Y; Inaba M; Ikeda H; Arai D; Maruyama H; Hara S; Tsumura S; Morinaga J; Sakagami T
    Eur J Cancer; 2021 Dec; 159():144-153. PubMed ID: 34749119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study.
    Igawa S; Fukui T; Kasajima M; Ono T; Ozawa T; Kakegawa M; Kusuhara S; Sato T; Nakahara Y; Hisashi M; Sasaki J; Naoki K
    Invest New Drugs; 2022 Apr; 40(2):430-437. PubMed ID: 34807331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world data on treatment outcomes in
    Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
    Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
    N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B).
    Tsubata Y; Watanabe K; Saito R; Nakamura A; Yoshioka H; Morita M; Honda R; Kanaji N; Ohizumi S; Jingu D; Nakagawa T; Nakazawa K; Mouri A; Takeuchi S; Furuya N; Akazawa Y; Miura K; Ichihara E; Maemondo M; Morita S; Kobayashi K; Isobe T
    Int J Clin Oncol; 2022 Jan; 27(1):112-120. PubMed ID: 34643820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osimertinib for
    Xie L; Nagpal S; Wakelee HA; Li G; Soltys SG; Neal JW
    Oncologist; 2019 Jun; 24(6):836-843. PubMed ID: 30126856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer.
    Liu X; Hong L; Nilsson M; Hubert SM; Wu S; Rinsurongkawong W; Lewis J; Spelman A; Roth J; Swisher S; He Y; Jack Lee J; Fang B; Heymach JV; Zhang J; Le X
    Lung Cancer; 2020 Nov; 149():33-40. PubMed ID: 32956986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status.
    Taniguchi Y; Tamiya A; Osuga M; Harada D; Isa SI; Nakamura K; Mizumori Y; Shinohara T; Yanai H; Nakatomi K; Oki M; Mori M; Kuwako T; Yamazaki K; Tamura A; Ando M; Koh Y
    BMC Pulm Med; 2024 Aug; 24(1):407. PubMed ID: 39182046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
    van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ
    Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.